Evidence map›Paper›PMID 39547244›Full record

SynthesisThe Lancet. Microbe2025

Performance of stool-based molecular tests and processing methods for paediatric tuberculosis diagnosis: a systematic review and meta-analysis.

Lucía Carratalà-Castro, Shilzia Munguambe, Belén Saavedra-Cervera, Petra de Haas, Alexander Kay, Olivier Marcy, Pamela Nabeta, Willy Ssengooba, Elisabetta Ghimenton-Walters, Sozinho Acácio and 10 more

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in The Lancet. Microbe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Closing gaps through innovation in the tuberculosis pathology value chain.Journal of clinical tuberculosis and other mycobacterial diseases · 2026
    Review
  4. Article
  5. Article
  6. Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  7. Expert review of respiratory medicine · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lucía Carratalà-CastroCentro de Investigação em Saúde de Manhiça, Manhiça, Mozambique; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Shilzia MunguambeCentro de Investigação em Saúde de Manhiça, Manhiça, Mozambique.
Belén Saavedra-CerveraCentro de Investigação em Saúde de Manhiça, Manhiça, Mozambique; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Wellcome Sanger Institute, Hinxton, UK.
Petra de HaasKNCV Tuberculosis Foundation, The Hague, Netherlands.
Alexander KayBaylor College of Medicine, Houston, TX, USA; Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.
Olivier MarcyUniversity of Bordeaux, Inserm U1219, IRD EMR271, Bordeaux, France.
Pamela NabetaFIND, Geneva, Switzerland.
Willy SsengoobaDepartment of Medical Microbiology, Makerere University, Kampala, Uganda.
Elisabetta Ghimenton-WaltersDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK; North Tees and Hartlepool NHS Foundation Trust, Hardwick Road, Stockton on Tees, UK.
Sozinho AcácioCentro de Investigação em Saúde de Manhiça, Manhiça, Mozambique.
Maryline BonnetTransVIHMI, University of Montpellier, IRD, INSERM, Montpellier, France.
Joanna EhrlichISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Andrew R DiNardoBaylor College of Medicine, Houston, TX, USA; Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini; Radboud University Medical Centre, Nijmegen, Netherlands.
Anca VasiliuBaylor College of Medicine, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Germany.
Christoph LangeBaylor College of Medicine, Houston, TX, USA; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Germany; Respiratory Medicine andInternational Health, University of Lübeck, Lübeck, Germany.
Sabine HermansAmsterdam University Medical Centre, University of Amsterdam, Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; Amsterdam University Medical Centre, University of Amsterdam, Centre for Tropical and Travel Medicine, Department of Infectious Diseases, Amsterdam, Netherlands.
Anna M MandalakasBaylor College of Medicine, Houston, TX, USA; Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini; Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Germany.
Elisa López-VarelaISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Alberto L García-BasteiroCentro de Investigação em Saúde de Manhiça, Manhiça, Mozambique; ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Barcelona, Spain; Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain. Electronic address: alberto.garcia-basteiro@manhica.net.
Stool4TB Global Partnership

Funding

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment MonitoringR01AI137527 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MANDALAKAS, ANNA M · 2019 to 2022
$2.7M
Siyakhula: Growing HIV/TB Research Knowledge for Growing Healthy Kids in EswatiniD43TW011547 · FIC · BAYLOR COLLEGE OF MEDICINE · PI MANDALAKAS, ANNA M · 2021 to 2025
$1.7M
Wastewater surveillance to enhance the public health response to HIV and TB in EswatiniDP1HD115427 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI Alexander William Kay · 2024 to 2026
$1.7M
Persistent DNA Hyper-Methylation of the IFN-γ Signaling Pathway During TuberculosisK23AI141681 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI DINARDO, ANDREW R · 2019 to 2023
$947k
Developing Clinical Prediction Tools to Define Strategies for Differentiated Service Delivery in Children and Adolescents Living with HIV in sub-Saharan Africa.K01TW011482 · FIC · BAYLOR COLLEGE OF MEDICINE · PI KAY, ALEXANDER WILLIAM · 2020 to 2024
$749k
FIC NIH HHS D43 TW011547FIC NIH HHS K01 TW011482NIAID NIH HHS K23 AI141681NIAID NIH HHS L40 AI120100NIAID NIH HHS R01 AI137527NICHD NIH HHS DP1 HD115427
6 · The paper itself

Abstract

backgroundThere has been a global pursuit to improve the diagnosis of tuberculosis in young children by applying diagnostic methods on accessible biospecimens such as stool. We aimed to conduct a systematic review on the accuracy of stool-based molecular tests for tuberculosis diagnosis in children and to assess the impact of the available pre-processing methods and other design characteristics.

methodsIn this systematic review and meta-analysis, we evaluated studies in children younger than 16 years with presumptive tuberculosis that were published in English, Spanish, French, and Portuguese from Jan 1, 2000, to May 3, 2024, in MEDLINE, Embase, and Embase Classic, comparing the molecular detection of Mycobacterium tuberculosis DNA in stool with microbiological tests on other samples or a clinical diagnosis. We did not exclude studies based on geographical location, sample size, or study design if they were reporting primary data. Two independent reviewers (LC-C and SM) screened titles, abstracts, and full-text articles for eligibility and extracted data on study characteristics, study population, and diagnostic performance. If information relevant to the main analysis was not reported in the article, the corresponding authors were contacted. Point estimates and 95% CIs were calculated for sensitivity and specificity for each study and for the different molecular tests (Xpert MTB/RIF, Xpert Ultra MTB/RIF [Cepheid, Sunnyvale, CA, USA], and other tests) versus a reference standard (culture only, any bacteriological confirmation, and tuberculosis case definition). Sensitivity and specificity were stratified by the stool processing method. We also quantified the additionality of stool Xpert Ultra tests for tuberculosis bacteriological confirmation. The protocol was registered with PROSPERO, CRD42022341514.

findingsA total of 4521 records were identified through the database search, one record was identified from an article bibliography, and 67 studies were retained for full-text reading. 39 studies were included in the qualitative synthesis, 35 of which were included in the meta-analyses. When using any bacteriological confirmation from a respiratory sample as the reference standard, stool Xpert sensitivity was 0·60 (95% CI 0·48-0·71), stool Xpert Ultra sensitivity was 0·73 (0·63-0·81), and sensitivity was 0·44 (0·29-0·60) for other in-house molecular methods combined. When using tuberculosis case definition as the reference standard, stool Xpert sensitivity was 0·23 (0·11-0·41), stool Xpert Ultra sensitivity was 0·38 (0·22-0·56), and sensitivity was 0·17 (0·09-0·23) for other in-house molecular methods. The addition of stool Xpert Ultra increased bacteriological confirmation of tuberculosis by 38·6% overall. Further, the utilisation of centrifuge-free simplified methods improved the sensitivity of stool Xpert Ultra when using any bacteriological confirmation as a reference standard (0·77 [0·66-0·85] for centrifuge-free methods vs 0·61 [0·41-0·78] for non-centrifuge-free methods).

interpretationThis systematic review and meta-analysis supports the use of Xpert Ultra in stool samples as a diagnostic tool for paediatric tuberculosis diagnosis. Stool-based Xpert Ultra can contribute to increase the bacteriological confirmation in this population, even when respiratory specimens are also tested.

fundingThe EDCTP2 programme supported by the EU via Stool4TB Project and the European Society of Pediatric Infectious Diseases.

Indexed as

FecesMolecular Diagnostic TechniquesMycobacterium tuberculosisTuberculosisAdolescentChildChild, PreschoolDNA, BacterialHumansInfantSensitivity and SpecificityDNA, Bacterial

Identifiers

PMID39547244
PMCPMC12062341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.